FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for treating multiple myeloma in a subject. That is ensured by administering a therapeutically effective amount of the CD38 antibody and a therapeutically effective amount of the lenalidomide compound to the subject.
EFFECT: invention provides treating multiple myeloma in a subject.
20 cl, 2 tbl, 14 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS COMPRISING ANTIBODY TO CD38 AND CARFILZOMIB | 2014 |
|
RU2670127C2 |
| COMPOSITIONS COMPRISING CD38 ANTIBODIES AND CARFILZOMIB | 2014 |
|
RU2723937C2 |
| ANTI-CD38 ANTIBODY AND LENALTDOMID OR BORTEZOMIB FOR TREATING MULTIPLE MYELOMA AND NHL | 2011 |
|
RU2595839C2 |
| AGENT FOR TREATING MULTIPLE MYELOMA (MM) | 2016 |
|
RU2723047C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| METHODS, THERAPY AND USE FOR TREATING MALIGNANT GROWTH | 2021 |
|
RU2831425C1 |
| RECOMBINANT IMMUNOTOXIN AIMED AT MESOTHELIN | 2012 |
|
RU2600067C2 |
| HUMAN ANTI-CD38-ANTIBODIES AND THEIR APPLICATION | 2005 |
|
RU2402568C2 |
| ANTIBODIES TO CD38 AND PHARMACEUTICAL COMPOSITIONS BASED THEREON FOR TREATMENT OF AUTOIMMUNE DISEASE MEDIATED BY AUTOANTIBODIES | 2020 |
|
RU2809565C2 |
